Premium
Burden of hereditary transthyretin amyloidosis on quality of life
Author(s) -
Yarlas Aaron,
Gertz Morie A.,
Dasgupta Noel R.,
Obici Laura,
Pollock Michael,
Ackermann Elizabeth J.,
Lovley Andrew,
Kessler Asia Sikora,
Patel Pankaj A.,
White Michelle K.,
Guthrie Spencer D.
Publication year - 2019
Publication title -
muscle and nerve
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.025
H-Index - 145
eISSN - 1097-4598
pISSN - 0148-639X
DOI - 10.1002/mus.26515
Subject(s) - medicine , amyloidosis , quality of life (healthcare) , polyneuropathy , transthyretin , population , peripheral neuropathy , diabetes mellitus , cardiac amyloidosis , heart failure , physical therapy , endocrinology , nursing , environmental health
Hereditary transthyretin (hATTR) amyloidosis is a progressive, degenerative disease, with peripheral neuropathy, cardiomyopathy, and other clinical manifestations. In this study we examine the impact of hATTR amyloidosis on quality of life (QOL). Methods Neuropathy‐specific QOL, measured with the Norfolk QOL‐Diabetic Neuropathy questionnaire, was compared between patients with hATTR amyloidosis and patients with type 2 diabetes, whereas generic QOL, measured with the 36‐item Short Form Health Survey version 2 (SF‐36v2), was compared between patients with hATTR amyloidosis, the general population, and patients with chronic diseases. Results Neuropathy‐specific QOL for patients with hATTR amyloidosis was nearly equivalent to that of patients with type 2 diabetes with diabetic neuropathy accompanied by a history of ulceration, gangrene, or amputation. Generic QOL was worse than that seen in the general population, with physical functioning worse than that for patients with multiple sclerosis and congestive heart failure. Discussion Patients with hATTR amyloidosis show significant burden on QOL, particularly in physical functioning. Muscle Nerve 60 : 169–175, 2019